

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT AND BUSINESS DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Doxofylline has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Doxofylline is mainly used in treatment of difficulty in breathing due to bronchial asthma, chronic asthmatic bronchitis and other bronchospasm.

In addition, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of China issued the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (Year 2022) (國家基本醫療保險、工傷保險和生育保險藥品目錄 (2022年)) (the “National Essential Drug List”), which shall be officially implemented from 1 March 2023. The Board is pleased to announce that a total of 96 products of the Group have been included in the National Essential Drug List. Among which, the Group’s new product Lacosamide Injection (20ml:0.2g) was included for the first time in “negotiation medicines within agreed period section” (協定期內談判藥品部分) and another new product Blonanserin Tablets was transferred to conventional “western medicines section” (西藥部分) of the National Essential Drug List, which are expected to bring growth in sales of the two new products. Lacosamide Injection is mainly used in combination therapy for partial-onset seizures in epilepsy patients. Blonanserin Tablets is mainly used in treatment of schizophrenia, and the Group was the first domestic entity in China being approved for drug production and registration for Blonanserin Tablets.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 19 January 2023

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.